EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco

Table 1

Clinical and molecular data.

Gender
Male	39
Female	26
Age (mean/median/range)	45.89/50/(8–83)
≤40 years	36 (55.38%)
>40 years	29 (44.62%)
KPS
>70	60 (92.31%)
≤70	5 (7.69%)
Tumor location
Frontal	26 (40%)
Parietal	5 (7.69%)
Temporal	8 (12.31%)
Occipital	1 (1.54%)
Two cerebral lobes affected	23 (35.38%)
Other	2 (3.08%)
Extent of surgery
Complete resection	43 (66.15%)
Partial resection	15 (23.08%)
Biopsy	7 (10.77%)
IDH gene
Mutant	8 (12.31%)
Wild type	57 (87.69%)
EGFR gene
Amplified	17 (26.15%)
Not amplified	48 (73.85%)

This table summarizes the clinicopathological features and molecular results concerning our study population of 65 Moroccan patients with glioblastomas.